Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634875 | 1.00 | SMYD3 (0.43) | SMYD3CA2CA1MTNR1ANPC1 | |
| Carbamic Acid SCHEMBL1271067 | 0.92 | SMYD3 (0.44) | SMYD3CA2CA1MTNR1AMAPT | |
| SCHEMBL7365470 | 0.83 | MTNR1A (0.40) | SMYD3CA2CA1MTNR1ANPC1 | |
| SCHEMBL5261942 | 0.83 | NPC1 (0.42) | SMYD3CA2CA1MTNR1ANPC1 | |
| SCHEMBL7419730 | 0.83 | MTNR1A (0.43) | SMYD3CA2CA1MTNR1ANPC1 | |
| SCHEMBL3139036 | 0.82 | GAA (0.47) | SMYD3CA2CA1MTNR1AMAPT | |
| Hydrochloric Acid SCHEMBL16353531 | 0.81 | MTNR1A (0.43) | SMYD3CA2CA1MTNR1ANPC1 | |
| SCHEMBL16618729 | 0.80 | MTNR1A (0.39) | SMYD3CA2CA1MTNR1ANPC1 | |
| SCHEMBL17163829 | 0.79 | MTNR1A (0.41) | SMYD3CA2CA1MTNR1ANPC1 | |
| SCHEMBL7823822 | 0.75 | ESR1 (0.44) | SMYD3MTNR1ANPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108503584-B | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof | 复旦大学 | 2021-05-04 | — | — | CN | claimed |
| CN-108503584-A | A kind of 1,2,3,4- tetrahydroquinolines sulfamide compound and its application | 复旦大学 | 2018-09-07 | — | — | CN | claimed |
| WO-2016044771-A1 | HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | claimed |
| EP-2563761-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-03-06 | — | — | EP | claimed |
| WO-2011137089-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | claimed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | claimed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | claimed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | claimed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | claimed |
| US-11641857-B2 | Unusually potent ABA receptor pan-antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11440887-B2 | Substituted 1,2,3,4-tetrahydroquinolines as inhibitors of repair enzyme 8-oxoguanine deoxyribonucleic acid glycosylase activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-09-13 | — | — | US | disclosed |
| CN-108503584-B | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof | 复旦大学 | 2021-05-04 | — | — | CN | disclosed |
| CN-108503584-B | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof | 复旦大学 | 2021-05-04 | — | — | CN | disclosed |
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008061373-A1 | COMBINATION TREATMENTS FOR ALZHEIMER'S DISEASE AND SIMILAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440887-B2 | Substituted 1,2,3,4-tetrahydroquinolines as inhibitors of repair enzyme 8-oxoguanine deoxyribonucleic acid glycosylase activity | OGG1, UNG, MPG | SMYD3 2325/4885CA2 4258/4885CA1 4464/4885 |
| US-11641857-B2 | Unusually potent ABA receptor pan-antagonists | AAK1, ATP5PO, BROX | SMYD3 4598/4885CA2 1123/4885CA1 2694/4885 |
| US-20200190034-A1 | Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon | OGG1, UNG, MPG | SMYD3 3827/4885CA2 3900/4885CA1 4333/4885 |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR7 | SMYD3 2193/4885CA2 2348/4885CA1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.